Literature DB >> 15893003

Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.

Charlotte Elberling Almasi1, Gunilla Høyer-Hansen, Ib Jarle Christensen, Keld Danø, Helle Pappot.   

Abstract

OBJECTIVES: The purpose of this study was to determine the prognostic impact of liberated domain I of the urokinase plasminogen activator receptor, uPAR(I), in tumour extracts from patients resected for the squamous cell carcinoma (SCC) of the lung.
MATERIALS AND METHODS: A recently developed time-resolved fluoroimmunoassay for uPAR(I), TR-FIA 3, was validated using a pool of SCC tumour extracts. This assay was then used to measure the levels of uPAR(I) in tumour extracts from 63 SCC patients. Overall survival of the patients was measured from the day of surgical resection until death or until a review after a median of 144 months observation. The Cox proportional hazard model was used for uni- and multivariate survival analysis.
RESULTS: TR-FIA 3 was found to measure uPAR(I) in SCC tumour extracts with high precision, accuracy and specificity. Univariate analysis using log transformed uPAR(I) concentrations showed that there was an increasing risk of mortality with increasing uPAR(I) levels in SCC tumour extracts, the hazard ratio (HR) being 2.9 with a P-value of 0.003. In a multivariate analysis, including uPAR(I), gender, age, nodal status, tumour size and levels of uPAR immunoreactivity measured by ELISA, statistically significant prognostic impact was found only for levels of uPAR(I) (HR 3.7, P=0.002) and tumour size (HR 2.4, P=0.02).
CONCLUSION: uPAR(I) levels in the extracts of primary tumours independently predicted overall survival of 63 patients with SCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893003     DOI: 10.1016/j.lungcan.2004.11.020

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  5 in total

1.  Prognostic value of urokinase plasminogen activator system in non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Jia-Ju Lu; Hong Guo; Bo Gao; Yun Zhang; Qing-Ling Lin; Jiang Shi; Jing-Jing Liu; Jian Liu
Journal:  Mol Clin Oncol       Date:  2017-11-03

2.  A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.

Authors:  Toru Sasaki; Hirotaka Nishi; Chie Nagata; Takeshi Nagai; Toshitaka Nagao; Fumitoshi Terauchi; Keiichi Isaka
Journal:  Int J Clin Oncol       Date:  2014-01-30       Impact factor: 3.402

3.  Identification of uPAR-positive chemoresistant cells in small cell lung cancer.

Authors:  Margarita Gutova; Joseph Najbauer; Anna Gevorgyan; Marianne Z Metz; Yehua Weng; Chu-Chih Shih; Karen S Aboody
Journal:  PLoS One       Date:  2007-02-28       Impact factor: 3.240

4.  Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.

Authors:  A F Lomholt; G Høyer-Hansen; H J Nielsen; I J Christensen
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

5.  Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.

Authors:  Line H Dohn; Peter Thind; Lisbeth Salling; Henriette Lindberg; Sofie Oersted; Ib J Christensen; Ole D Laerum; Martin Illemann; Hans von der Maase; Gunilla Høyer-Hansen; Helle Pappot
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.